» Articles » PMID: 32805423

Hashimoto's Thyroiditis: An Update on Pathogenic Mechanisms, Diagnostic Protocols, Therapeutic Strategies, and Potential Malignant Transformation

Overview
Journal Autoimmun Rev
Publisher Elsevier
Date 2020 Aug 18
PMID 32805423
Citations 184
Authors
Affiliations
Soon will be listed here.
Abstract

Hashimoto's thyroiditis, characterized by thyroid-specific autoantibodies, is one of the commonest autoimmune disorders. Although the exact etiology has not been fully elucidated, Hashimoto's thyroiditis is related to an interaction among genetic elements, environmental factors and epigenetic influences. Cellular and humoral immunity play a key role in the development of the disease; thus, a T and B cells inflammatory infiltration is frequently found. Histopathologic features of the disease include lymphoplasmacytic infiltration, lymphoid follicle formation with germinal centers, and parenchymal atrophy. Moreover, the occurrence of large follicular cells and oxyphilic or Askanazy cells is frequently associated to Hashimoto's thyroiditis. Clinically, Hashimoto's thyroiditis is characterized mainly by systemic manifestations due to the damage of the thyroid gland, developing a primary hypothyroidism. Diagnosis of Hashimoto's thyroiditis is clinical and based on clinical characteristics, positivity to serum antibodies against thyroid antigens (thyroid peroxidase and thyroglobulin), and lymphocytic infiltration on cytological examination. The mainstream of treatment is based on the management of the hypothyroidism with a substitution therapy. A relationship between Hashimoto's thyroiditis and a possible malignant transformation has been proposed in several studies and involves immunological/hormonal pathogenic links although specific correlation is still debated and needs to be further investigated with prospective studies.

Citing Articles

Evaluation of Serum CTRP-4 and CTRP-12 Levels in Hashimoto's Thyroiditis Patients: A Comparative Analysis with a Control Group and Their Correlation with Biochemical Factors.

Al-Husseini D, Saravani M, Nosratzehi S, Akbari H, Shafiei A, Jafari S Iran J Pathol. 2025; 20(1):42-48.

PMID: 40060227 PMC: 11887634. DOI: 10.30699/ijp.2024.2025001.3276.


Identification of BTK as an immune-related biomarker for Hashimoto's thyroiditis by integrated bioinformatic analysis.

Liu Y, Zhu Z, Xu Q, Xu J, Xing J, Wang S BMC Immunol. 2025; 26(1):11.

PMID: 40022006 PMC: 11869739. DOI: 10.1186/s12865-025-00691-x.


Assessment of causal association between autoimmune thyroiditis and thyroid cancer: A Mendelian randomization study.

Zhang Q, Lan X Medicine (Baltimore). 2025; 104(9):e41633.

PMID: 40020149 PMC: 11875592. DOI: 10.1097/MD.0000000000041633.


Recent advances in nanomedicine for the diagnosis and therapy of thyroid disorders.

Sahare P, Ruiz-Manriquez L, Anguiano B, Banerjee A, Pathak S, Duttaroy A 3 Biotech. 2025; 15(3):67.

PMID: 40012722 PMC: 11850684. DOI: 10.1007/s13205-025-04234-4.


Correlation analysis of Hashimoto's thyroiditis with papillary thyroid carcinoma occurrence and its central lymph node metastasis: a single center experience.

Sun K, Wang X, Chen D, Ma C Front Endocrinol (Lausanne). 2025; 15:1420998.

PMID: 39981137 PMC: 11840962. DOI: 10.3389/fendo.2024.1420998.